All In Biotech

Drug Trial Radar · NCT00891202

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE)

Last checked: Nov 19, 2026Latest source record: Mar 3, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

40

Actual

Start

Nov 2009

Primary completion

Jul 2012

Study completion Jan 2016

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
May 1, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study was designed to confirm the efficacy and safety of eliglustat tartrate (Genz-112638) in participants with Gaucher disease Type 1.

Conditions

  • Gaucher Disease, Type 1

Interventions

  • Eliglustat tartrateDrug

    PAP: Eliglustat tartrate (ET) capsule 50 mg orally on Day 1 followed by ET 50 mg capsule twice daily (BID) from Day 2 to Week 4, then either ET 50 mg capsule BID (participants with Genz-99067 \[active moiety of ET in plasma\] trough plasma concentration \>=5 ng/mL) or ET 100 mg capsule BID (participants with Genz-99067 trough plasma concentration \<5 ng/mL), up to Week 39. PK assessment at Week 2 used for dose adjustment after Week 4. LTTP: Participants of the eliglustat arm in PAP who completed PAP were included in LTTP and received ET capsule 50 mg BID orally from Day 1 (post Week 39) until Week 43 followed by ET 50 mg or 100 mg capsule BID up to Week 47, then ET 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.

  • PlaceboDrug

    PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PAP: Percent Change From Baseline in Spleen Volume (in Multiples of Normal [MN]) at Week 39 of the Primary Analysis Period With Eliglustat Tartrate Treatment as Compared to PlaceboTime frame: PAP Baseline (Day 1), Week 39

Locations

18 sites in 12 countries. Site status is shown where the registry gives one.

  • UCSF MS Center

    San Francisco, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • Emory University Medical Genetics

    Decatur, Georgia

  • University of Kansas Medical Center, Division of Hematology/Oncology, Dept. of Medicine

    Westwood, Kansas

  • New York University School of Medicine, Neurology Department

    New York, New York

  • Mount Sinai School of Medicine

    New York, New York

  • University hospital "Alexandrovska" Sofia

    Sofia, Bulgaria

  • Sir Mortimer B. Davis - Jewish General Hospital

    Montreal, Quebec, Canada

  • Mount Sinai Hospital and the Samuel Lunenfeld Research Institute

    Toronto Ontario, Canada

  • Hospital de San Jose

    Bogotá, Colombia

  • Christian Medical College Hospital

    Vellore, India

  • Rabin Medical Center, Beilinson Hospital

    Petach Tikvah, Israel

  • Hôtel-Dieu de France University Hospital

    Beirut, Lebanon

  • OCA Hospital

    Monterrey, Nuevo Leon, Mexico

  • Hematology Research Center of Ministry of Healthcare of the Russian Federation

    Moscow, Russia

  • Institut za endokrinologiju

    Belgrade, Serbia

  • Hopital La-Rabta

    Tunis, TN, Tunisia

  • Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.